BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15114602)

  • 1. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral iron therapy: a single institution's experience over a 5-year period.
    Laman CA; Silverstein SB; Rodgers GM
    J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
    Fishbane S; Kowalski EA
    Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
    Sane R; Baribeault D; Rosenberg CL
    Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
    Fishbane S; Wagner J
    Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of available intravenous iron preparations in hemodialysis.
    Palmer K; Cameron K; Battistella M
    CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative rates of adverse events with different formulations of intravenous iron.
    Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
    Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should intravenous iron be upfront therapy for iron deficiency anemia?
    Auerbach M
    Pediatr Blood Cancer; 2011 Apr; 56(4):511-2. PubMed ID: 21298731
    [No Abstract]   [Full Text] [Related]  

  • 10. Addressing patient concerns about intravenous iron therapy.
    Robbins KC
    Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parenteral iron replacement].
    Cynke E
    Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Importance of the different i.v. iron generations for everyday medical practice].
    Biggar P; Hahn KM
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Safety aspects of parenteral iron supplementation therapies in patients with chronic kidney disease].
    Potthoff SA; Münch HG
    Dtsch Med Wochenschr; 2013 Jun; 138(24):1312-7. PubMed ID: 23737117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparative Look at the Safety Profiles of Intravenous Iron Products Used in the Hemodialysis Population.
    Coppol E; Shelly J; Cheng S; Kaakeh Y; Shepler B
    Ann Pharmacother; 2011 Feb; 45(2):241-7. PubMed ID: 21304025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety aspects of parenteral iron in patients with end-stage renal disease.
    Sunder-Plassmann G; Hörl WH
    Drug Saf; 1997 Oct; 17(4):241-50. PubMed ID: 9352960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Use of Parenteral Iron Therapy for the Treatment of Postpartum Anemia.
    Nash CM; Allen VM
    J Obstet Gynaecol Can; 2015 May; 37(5):439-442. PubMed ID: 26168105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral iron dextran therapy: a review.
    Burns DL; Mascioli EA; Bistrian BR
    Nutrition; 1995; 11(2):163-8. PubMed ID: 7647482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.